Tratamiento de la hipertension portal con nadolol en pacientes con cirrosis hepatica.

Cervera, J; Torres Zamora, M; Gutierrez Carreno, R; Fierro, M; Schaeffer, L; Landa, L.
Arch. invest. méd ; 14(4): 331-41, 1983.
Artículo en Español | LILACS | ID: lil-19548

Documentos relacionados

  1. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis.
  2. Mechanism and application of ß-adrenoceptor blockers in soft tissue wound healing.
  3. Enantiocomplementary synthesis of ß-adrenergic blocker precursors via biocatalytic nitration of phenyl glycidyl ethers.
  4. Selection of patients with portal hypertension and cirrhosis who will benefit from beta-blockers: Still a current challenge.
  5. [Beta-blockers : myths and facts].
  6. Continuation of nonselective beta-blockers for patients with liver cirrhosis and hemodynamic nonresponse?
  7. In compensated cirrhosis with portal hypertension, ß-blockers reduced a composite of decompensation or death.
  8. Prevention of decompensation in cirrhosis: a new youth for ß blockers.
  9. Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension?
  10. Evaluation of advanced oxidation processes for ß-blockers degradation: a review.